Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 16/07/2024 pm IST			5-day change	1st Jan Change
970 ^DKK	-0.34%		+0.41%	+38.95%

16/07	Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron	DJ
16/07	Novo owner backs Swiss biotech Asceneuron in $100 million round	RE

NOVO NORDISK : Receives a Buy rating from Deutsche Bank

January 10, 2024 at 05:34 pm IST

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. Previously set at DKK 775, the target price has been raised to DKK 850.

Latest news about Novo Nordisk A/S

Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron	16/07	DJ
Novo owner backs Swiss biotech Asceneuron in $100 million round	16/07	RE
Health Care Declines on Regulatory Fears - Health Care Roundup	16/07	DJ
European Equities Close Lower in Monday Trading; Luxury Goods Stocks Fall as Burberry Reports 'Disappointing' Q1 Results, Fires CEO	15/07	MT
Novo Nordisk Says No Meeting Scheduled With US Senate Aides, Senior Executives	15/07	MT
Novo Nordisk Reported to Meet Senate Staff Over Decision to Discontinue Levemir Insulin	15/07	MT
Novo Nordisk Denies Reported Meeting with US Senate Aides Over Insulin Discontinuation	15/07	MT
Novo Nordisk to Meet US Senate Aides Over Levemir Insulin Sales Halt	15/07	MT
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	12/07	RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs	12/07	MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	12/07	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	12/07	RE
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says	12/07	MT
NOVO NORDISK : Buy rating from Deutsche Bank	12/07	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	12/07	DJ
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	11/07	MT
Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan...	11/07
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	11/07	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	11/07	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	11/07	MT
Pfizer moves forward with once-daily weight loss drug	11/07	RE
Novo Nordisk Gets Complete Response Letter from US FDA for Insulin Icodec Application	11/07	MT
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	11/07	ZD
NOVO NORDISK : JP Morgan reaffirms its Buy rating	11/07	ZD

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 10:06 pm IST

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 09:39 pm IST

Novo Nordisk doesn't disappoint

January 31, 2024 at 09:18 pm IST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

970 DKK

Average target price

957.1 DKK

Spread / Average Target

-1.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+38.95%	631B
ELI LILLY AND COMPANY	+61.53%	856B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B
SANOFI	+2.41%	126B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Receives a Buy rating from Deutsche Bank

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals